MSAC publishes agenda for November 2022 meeting


27 July 2022 - 12 agenda items for consideration at the 24-25 November 2022 meeting.

The assessments of note are:

  • Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma
  • KRAS G12C variant testing in patients with locally advanced or metastatic non-small-cell lung cancer to determine eligibility for sotorasib as second-line therapy
  • PD-L1 immunohistochemistry testing in patients with persistent, recurrent, or metastatic cervical cancer to determine eligibility for pembrolizumab
  • Brexucabtagene autoleucel for adult relapsed or refractory B-precursor acute lymphoblastic leukaemia

Read MSAC agenda

Michael Wonder

Posted by:

Michael Wonder